97 related articles for article (PubMed ID: 27084920)
1. Pharmacokinetics and pharmacodynamics of oleylphosphocholine in a hamster model of visceral leishmaniasis.
Fortin A; Dorlo TP; Hendrickx S; Maes L
J Antimicrob Chemother; 2016 Jul; 71(7):1892-8. PubMed ID: 27084920
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.
Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L
J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
Corral MJ; Serrano DR; Moreno I; Torrado JJ; Domínguez M; Alunda JM
J Antimicrob Chemother; 2014 Dec; 69(12):3268-74. PubMed ID: 25096077
[TBL] [Abstract][Full Text] [Related]
4. First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum.
Hernández L; Gálvez R; Montoya A; Checa R; Bello A; Bosschaerts T; Jansen H; Rupérez C; Fortin A; Miró G
Parasitol Res; 2014 Jan; 113(1):157-64. PubMed ID: 24192865
[TBL] [Abstract][Full Text] [Related]
5. Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis.
Fortin A; Caridha DP; Leed S; Ngundam F; Sena J; Bosschaerts T; Parriott S; Hickman MR; Hudson TH; Grogl M
PLoS Negl Trop Dis; 2014 Sep; 8(9):e3144. PubMed ID: 25210745
[TBL] [Abstract][Full Text] [Related]
6. Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis.
Eberhardt E; Mondelaers A; Hendrickx S; Van den Kerkhof M; Maes L; Caljon G
Parasitol Res; 2016 Oct; 115(10):4061-70. PubMed ID: 27412759
[TBL] [Abstract][Full Text] [Related]
7. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
[TBL] [Abstract][Full Text] [Related]
8. In vivo evaluation of anti-Leishmania activity of alkyltriazoles and alkylphosphocholines by oral route.
Gontijo VS; Colombo FA; Ferreira Espuri P; Freitas PG; Nunes JB; Alves LB; Veloso MP; Alves RB; Freitas RP; Marques MJ
Exp Parasitol; 2021; 226-227():108123. PubMed ID: 34144040
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic or therapeutic administration of Agaricus blazei Murill is effective in treatment of murine visceral leishmaniasis.
Valadares DG; Duarte MC; Ramírez L; Chávez-Fumagalli MA; Martins VT; Costa LE; Lage PS; Ribeiro TG; Castilho RO; Fernandes AP; Régis WC; Soto M; Tavares CA; Coelho EA
Exp Parasitol; 2012 Oct; 132(2):228-36. PubMed ID: 22824583
[TBL] [Abstract][Full Text] [Related]
10. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
Reimão JQ; Pita Pedro DP; Coelho AC
Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
Exp Parasitol; 2012 Mar; 130(3):195-9. PubMed ID: 22281156
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis.
Van Bocxlaer K; Dixon J; Platteeuw JJ; Van Den Heuvel D; Mcarthur KN; Harris A; Alavijeh M; Croft SL; Yardley V
J Antimicrob Chemother; 2023 Jul; 78(7):1723-1731. PubMed ID: 37229566
[TBL] [Abstract][Full Text] [Related]
13. Miltefosine-Lopinavir Combination Therapy Against
Rebello KM; Andrade-Neto VV; Gomes CRB; de Souza MVN; Branquinha MH; Santos ALS; Torres-Santos EC; d'Avila-Levy CM
Front Cell Infect Microbiol; 2019; 9():229. PubMed ID: 31316919
[TBL] [Abstract][Full Text] [Related]
14. Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.
de Vries PJ; van der Meide WF; Godfried MH; Schallig HD; Dinant HJ; Faber WR
Trans R Soc Trop Med Hyg; 2006 Dec; 100(12):1183-6. PubMed ID: 16678871
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and disposition of miltefosine in healthy mice and hamsters experimentally infected with Leishmania infantum.
Jiménez-Antón MD; García-Calvo E; Gutiérrez C; Escribano MD; Kayali N; Luque-García JL; Olías-Molero AI; Corral MJ; Costi MP; Torrado JJ; Alunda JM
Eur J Pharm Sci; 2018 Aug; 121():281-286. PubMed ID: 29883726
[TBL] [Abstract][Full Text] [Related]
16. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo evaluation using phosphatidylserine-liposomes.
Pinto EG; da Costa-Silva TA; Tempone AG
Acta Trop; 2014 Sep; 137():206-10. PubMed ID: 24905294
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.
Mbui J; Olobo J; Omollo R; Solomos A; Kip AE; Kirigi G; Sagaki P; Kimutai R; Were L; Omollo T; Egondi TW; Wasunna M; Alvar J; Dorlo TPC; Alves F
Clin Infect Dis; 2019 Apr; 68(9):1530-1538. PubMed ID: 30188978
[TBL] [Abstract][Full Text] [Related]
18. Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.
Le Fichoux Y; Rousseau D; Ferrua B; Ruette S; Lelièvre A; Grousson D; Kubar J
Antimicrob Agents Chemother; 1998 Mar; 42(3):654-8. PubMed ID: 9517947
[TBL] [Abstract][Full Text] [Related]
19. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
[TBL] [Abstract][Full Text] [Related]
20. A chronic bioluminescent model of experimental visceral leishmaniasis for accelerating drug discovery.
Álvarez-Velilla R; Gutiérrez-Corbo MDC; Punzón C; Pérez-Pertejo MY; Balaña-Fouce R; Fresno M; Reguera RM
PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007133. PubMed ID: 30763330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
